We can compare the relative efficacy of multiple sclerosis medications by examining the results of independent clinical trials: Yes

Abstract

Get full access to this article

View all access options for this article.

References

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

Lublin

Reingold

Cohen

. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83: 278–286.

Kurtzke

. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444–1452.

Vrenken

Jenkinson

Horsfield

. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 2013; 260: 2458–2471.

Durelli

Verdun

Barbero

. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2 year prospective randomized multicentre study (INCOMIN). Lancet 2002; 359: 1453–1460.

Koch-Henriksen

Sorensen

Christensen

. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006; 66: 1056–1060.

Panitch

Goodin

Francis

. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology 2002; 59: 1496–1506.

Cohen

Coles

Arnold

. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012; 380: 1819–1828.

Coles

Twyman

Arnold

. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012; 380: 1829–1839.

10.

Castellani

. Head to head; are clinical trial data shared sufficiently today? Yes. BMJ 2013; 347: f1881.

11.

Filippini

Del Giovane

Vacchi

. Immunomodulators and immunosuppressants for multiple sclerosis: Network meta-analysis. Cochrane Database Syst Rev 2013; 6: CD008933.

12.

Del Santo

Maratea

Fadda

. Treatments for relapsing-remitting multiple sclerosis: Summarising current information by network meta-analysis. Eur J Clin Pharmacol 2012; 68: 441–448.

13.

Hurwitz

. Registry studies of long-term multiple sclerosis outcomes: Description of key registries. Neurology 2011; 76(Suppl 1): S3–S6.

14.

Palace

Bregenzer

Tremlett

. UK multiple sclerosis risk-sharing scheme: A new natural history dataset and an improved Markov model. BMJ Open 2014; 4: e004073.